Prevention of disease with pharmaceuticals

Pharmacology and Toxicology

Volumn 88, Issue 3, 2001, Pages 111-118

  Vainio, Harri ^a   Bianchini, Franca ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; BETA CAROTENE; NONSTEROID ANTIINFLAMMATORY AGENT; STATIN;

CANCER; CANCER PREVENTION; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; DIET SUPPLEMENTATION; HIGH RISK POPULATION; HUMAN; LIFESTYLE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; SHORT SURVEY;

EID: 0035110499     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0773.2001.d01-91.x     Document Type: Short Survey

References (5)

1. Blot, W. J., J. Y. Li, P. R. Taylor, W. Guo, S. M. Dawsey & B. Li: The Linxian trials: mortality rates by vitamin-mineral intervention group. Amer. J. Clin. Nutr. 1995, 62, 1424S-1426S.
2. Blot, W. J., J. Y. Li, P. R. Taylor & B. Li: Lung cancer and vitamin supplementation. New Engl. J. Med. 1994, 331, 614-614.
3. Cummings, S. R., S. Eckert, K. A. Krueger, D. Grady, T. J. Powles, J. A. Cauley, L. Norton, T. Nickeisen, N. H. Bjarnason, M. Morrow, M. E. Lippman, D. Black, J. E. Glusman, A. Costa & V. C. Jordan: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 1999, 281, 2189-2197.
4. Delmas, P. D., N. H. Bjarnason, B. H. Mitlak, A. C. Ravoux, A. S. Shah, W. J. Huster, M. Draper & C. Christiansen: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New Engl. J. Med. 1997, 337, 1641-1647.
5. Ebrahim, S.: Cost-effectiveness of stroke prevention. Brit. Med. Bull. 2000, 56, 557-570.